Enterprise Value
-30.75M
Cash
165.8M
Avg Qtr Burn
-32.49M
Short % of Float
3.23%
Insider Ownership
1.02%
Institutional Own.
54.54%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tamibarotene (SY-1425) (RARα agonist) Details Cancer, Myelodysplastic syndrome Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
SM-88 Details Prostate Cancer | Phase 3 Update | |
Phase 3 Initiation | ||
Tamibarotene (SY-1425) (RARα agonist) in combination with venetoclax and azacitidin Details Acute myeloid leukemia, Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
SM-88 Details Breast cancer | Phase 2 Data readout | |
SM-88 Details Sarcoma, Bone cancer | Phase 2 Update | |
Failed Discontinued | ||
TYME-19 Details COVID-19 | Failed Discontinued | |
SM-88 Details Pancreatic cancer | Failed Discontinued |